Bastian et al. have shown that the combination of BTZ and histone deacetylase inhibitors have synergistic activity in preclinical models of B-cell precursor acute lymphoblastic leukemia through activating NF-κB signaling16. Here, NFKB1 is linked to precursor B-cell acute lymphoblastic leukemia.